Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties
出版年份 2013 全文链接
标题
Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties
作者
关键词
-
出版物
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 29, Issue 7, Pages 1284-1300
出版商
Oxford University Press (OUP)
发表日期
2013-12-10
DOI
10.1093/ndt/gft462
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
- (2013) Juan C. Arjona Ferreira et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes
- (2013) A.J. Scheen et al. DIABETES & METABOLISM
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
- (2013) T. Heise et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
- (2013) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
- (2013) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis
- (2013) Yuki Fujii et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus
- (2013) Damayanthi Devineni et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
- (2012) Yan-Ling He CLINICAL PHARMACOKINETICS
- One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment
- (2012) W. Kothny et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETOLOGIA
- Dapagliflozin: a review on efficacy, clinical effectiveness and safety
- (2012) Angela J Paisley et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Glitazones in chronic kidney disease: Potential and concerns
- (2012) D. Bolignano et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- DPP-4 inhibitors in the treatment of type 2 diabetes
- (2011) Hélène Duez et al. BIOCHEMICAL PHARMACOLOGY
- A Quantitative Approach to Drug Dosing in Chronic Kidney Disease
- (2011) Ali J. Olyaei et al. BLOOD PURIFICATION
- Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
- (2011) David W. Boulton et al. CLINICAL PHARMACOKINETICS
- Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice
- (2011) Masanori Abe et al. CURRENT DRUG METABOLISM
- Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
- (2011) K. J. Lipska et al. DIABETES CARE
- Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*
- (2011) U. Graefe-Mody et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
- (2011) V. Lukashevich et al. DIABETES OBESITY & METABOLISM
- The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis
- (2011) Midori Ito et al. ENDOCRINE JOURNAL
- Mild Renal Impairment and the Efficacy and Safety of Liraglutide
- (2011) Jaime A. Davidson et al. Endocrine Practice
- Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study
- (2011) M. Nowicki et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Metformin Use and Mortality Among Patients With Diabetes and AtherothrombosisMetformin Use With Diabetes and Atherothrombosis
- (2010) Ronan Roussel ARCHIVES OF INTERNAL MEDICINE
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
- (2010) S. Blech et al. DRUG METABOLISM AND DISPOSITION
- Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase
- (2010) M. Malm-Erjefalt et al. DRUG METABOLISM AND DISPOSITION
- Lactic Acidosis Induced by Metformin
- (2010) Jean-Daniel Lalau DRUG SAFETY
- Effect of a High-Fat Meal on the Pharmacokinetics of Saxagliptin in Healthy Subjects
- (2010) Chirag G. Patel et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements
- (2010) I. R. F. van Berlo-van de Laar et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
- (2009) Lisbeth V. Jacobsen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug
- (2009) Iskandar Idris et al. DIABETES OBESITY & METABOLISM
- In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
- (2009) M. Obermeier et al. DRUG METABOLISM AND DISPOSITION
- Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
- (2008) R CHRISTOPHER et al. CLINICAL THERAPEUTICS
- Altered nonrenal drug clearance in ESRD
- (2008) Thomas D Nolin CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
- (2008) J. C. N. Chan et al. DIABETES OBESITY & METABOLISM
- Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
- (2008) H. He et al. DRUG METABOLISM AND DISPOSITION
- The effect of chronic renal failure on drug metabolism and transport
- (2008) Albert W Dreisbach et al. Expert Opinion on Drug Metabolism & Toxicology
- Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists
- (2008) Fu Lin et al. JOURNAL OF MOLECULAR MODELING
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started